Back to the complete issue
Sunday, 28 June 2020

Acdima signs MoU with SK Plasma to produce plasma-derived products

Acdima Pharma signed an MoU with South Korea’s SK Plasma to produce plasma-derived medicinal products in Egypt, the local press reports, without providing additional details. Medical centers treating covid-19 have been experimenting with plasma therapy, administering antibody-rich blood from recovered patients to new ones through transfusions.

Enterprise is a daily publication of Enterprise Ventures LLC, an Egyptian limited liability company (commercial register 83594), and a subsidiary of Inktank Communications. Summaries are intended for guidance only and are provided on an as-is basis; kindly refer to the source article in its original language prior to undertaking any action. Neither Enterprise Ventures nor its staff assume any responsibility or liability for the accuracy of the information contained in this publication, whether in the form of summaries or analysis. © 2020 Enterprise Ventures LLC.